Abstract

Head and neck cancer (HNC) is the sixth most common human malignancy worldwide. The main forms of treatment for HNC are surgery, radiotherapy (RT) and chemotherapy (CT). However, the choice of therapy depends on the tumor staging and approaches, which are aimed at organ preservation. Because of systemic RT and CT genotoxicity, one of the important side effects is a secondary cancer that can result from the activity of radiation and antineoplastic drugs on healthy cells. Ionizing radiation can affect the DNA, causing single and double-strand breaks, DNA-protein crosslinks and oxidative damage. The severity of radiotoxicity can be directly associated with the radiation dosimetry and the dose-volume differences. Regarding CT, cisplatin is still the standard protocol for the treatment of squamous cell carcinoma, the most common cancer located in the oral cavity. However, simultaneous treatment with cisplatin, bleomycin and 5-fluorouracil or treatment with paclitaxel and cisplatin are also used. These drugs can interact with the DNA, causing DNA crosslinks, double and single-strand breaks and changes in gene expression. Currently, the late effects of therapy have become a recurring problem, mainly due to the increased survival of HNC patients. Herein, we present an update of the systemic activity of RT and CT for HNC, with a focus on their toxicogenetic and toxicogenomic effects.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Chemotherapy; Head and neck cancer; Radiotherapy; Toxicogenetic; Toxicogenomic

Core tip: The main therapies for head and neck cancer (HNC) are surgery, radiotherapy (RT) and chemotherapy. Considering that both RT and chemotherapeutical drugs can interact with the DNA, one of the important, late-occurring complications is a therapy-related secondary tumor resulting from the genotoxic effects of the therapy on the healthy cells. This review presents an update of the toxicogenetic and toxicogenomic effects of HNC treatments, highlighting the main mechanisms evolved in the secondary damage caused by RT and chemotherapies.

Minicucci EM, da Silva GN, Salvadori DMF. Relationship between head and neck cancer therapy and some genetic endpoints. World J Clin Oncol 2014; 5(2): 93-102 Available from: URL: http://www.wjgnet.com/2218-4333/full/v5/i2/93.htm DOI: http://dx.doi.org/10.5306/wjco.v5.i2.93

INTRODUCTION

Head and neck cancer (HNC) is the sixth most common
In recent years, RT has technically and biologically improved, aiming at including only the target, with minimal unnecessary irradiation to normal tissue[29,30]. Actually, RT fractionation schedules includes more fractions per day in order to reduce the overall treatment time (accelerated fractionation) and/or the use of multiple small fraction doses (hyperfractionation), which allows a higher total dose to be given without enhancing the risk of morbidity induced by radiation[31].

Radioresistance is one of the main determinants of treatment outcome in HNC patients, and it can be related to tumor hypoxia and changes in gene expression[32,33]. A meta-analysis study showed that when hypoxic modification is given in conjunction with curative intended RT result in a significant improvement in loco-regional control, disease specific control and overall survival[34]. However, another study showed that RT (5 Gy radiation) had no effect on hypoxia-inducible factor-1α (HIF-1α) gene expression in human oral SCC cell lines (SAS, Ca9-22, TT, BSC-OF and IS-FOM). Conversely, SCC cells expressing high levels of HIF-1α were resistant to radiation[35].

Several genes, such as sensors, transducers and effectors of DNA damage, have been associated with the ionizing radiation-induced cellular response[36]. One of the main molecules is the tumor-suppressor protein p53, which acts through the transcriptional control of target genes, influences multiple response pathways and leads to a diverse response to ionizing radiation in malian cells[37]. Additionally, one study demonstrated that the radiation-resistant capacity of nasopharyngeal tumors was mostly due to changes in expression of genes related to cell Ca2+ homeostasis. This same study also showed that cell proliferation induced by extracellular and intracellular factors may maintain the tumor size during RT, leading to recurrence after treatment[38].

Bohn et al[39] showed that RT induces a systemic stress response, as revealed by the induction of stress relevant gene expression in blood cells. However, the authors discuss that further studies are still needed to confirm that these changes reflect a systemic effect or are biomarkers of the tumor microenvironment. Moreover, a genomic (transcriptomic and proteomic) study of the response to radioresistance showed 265 up-regulated and 268 down-regulated genes, 30 of which were cancer-related genes. The proteomic analysis identified 51 proteins with altered expression in the radioresistant cell lines, 18 of which were cancer-related proteins. In both methodologies, the over-expression of NM23-H1 and PAX4 were identified[40]. The influence of GP96 protein in radioresistance has been also described[41,43]. GP96 is a multifunctional protein[42] that acts as a chaperon for peptides and modulates the innate and adaptive immune responses that are mediated by antigen-presenting cells and other immune cells[43,44]. Furthermore, GP96 is important for protein maturation and protein homeostasis[45]. In patients undergoing RT, it was shown that GP96 may serve as a novel prognostic marker of RT and may play important role in radioresistance, favoring tumor invasiveness[46].

In addition to gene expression changes, it is well
known that ionizing radiation damages the DNA, causing single (SSB) and double-strand breaks due to direct action or by the generation of free radicals\[47\], resulting in oxidative stress\[48\], base damage and DNA-protein cross-links\[49-51\]. The oxidative DNA damage arising from RT can be responsible for both therapeutic and adverse effects\[52\]. In other words, RT may kill the tumor cells, but it can also damage normal tissues\[53\]. A second tumor may develop immediately or years after the primary tumor treatment\[54\]. Therefore, the most important dose-limiting factor is the tolerance of the adjacent normal tissue, which depends on the stage and location of the primary tumor\[55\]. Quantification of chromosome aberrations in circulating lymphocytes is used to estimate the effects of the RT dose\[56\].

RT mutagenicity on tumor and healthy tissues depends on the DNA repair capacity\[57\]. Genomic integrity following irradiation is maintained by specific DNA repair pathways that are initiated based on the type of DNA damage\[58\]. Double-strand DNA breaks are repaired via homologous recombination repair and/or non-homologous end joining repair\[59\]. In HNC, variants of the XRCC2, XRCC3 and RAD-5 genes were found to be associated with acute mucositis\[60,61\]. The alkaline comet assay has become a popular technique for detecting a range of DNA damage types during the last decade\[62\], including the effects of RT. In this sense, DNA damage and repair efficiency were evaluated by comparing the peripheral blood lymphocytes, which were isolated from tissue biopsies and from metastases biopsies of SCC patients after treatment with gamma radiation (Cobalt 60). It was observed that the repair mechanisms were less effective in patients with metastasis than in the healthy controls. Thus, the differences in radiation sensitivity of the cancer and control cells suggest that DNA repair might be critical for the treatment of SCC\[63\]. On the other hand, the 8-oxoGua is one of the most common DNA lesions that results from reactive oxygen species (ROS)\[64\], and this lesion can lead to mismatched pairing\[65\]. The repair hOGG1 glycosylase removes 8-oxoGua from the cellular DNA and repairs the base excision\[66,67\]. Thus, Cooke et al.\[68\] showed that urinary excretion of 8-oxoGua and 8-oxodG can be used to measure the activity of the enzymes that are involved in the removal of oxidative DNA damage. In this sense, Roszkowski et al.\[69\] demonstrated that fractionated RT of HNC patients resulted in elevated urinary excretion of 8-oxodG and a significant reduction of uric acid in the blood. The authors suggested that the RT is responsible for oxidative stress/oxidative DNA damage throughout the whole body and, therefore, may be responsible for a significant increase in the level of 8-oxodG in a distinct subpopulation of HNC patients\[70\]. The lack of increase of urinary 8-oxoGua in irradiated patients may reflect a reduction in the activity of hOGG1. Recently, it has been observed that HNC patients have a significantly reduced ability to repair the 8-oxoGua lesion that is generated by oxidative stress\[71\]. However, the decreased activity of the main enzyme responsible for 8-oxoGua removal should result in the accumulation of the lesion in cellular DNA\[72\]. Some authors have also shown different inter-individual responses in patients after RT. Kadam et al.\[73\] studied gamma radiation-induced SSBs in peripheral blood leukocytes of SCC HNC patients with different lifestyles, both during and after RT. The results indicated that gamma radiation caused considerable DNA damage in all of the dose intervals of the treatment. However, a comparison between the smokers and non-smokers revealed the significantly greater DNA damage in the smoking patients at the pre-therapy level (10 Gy and 60 Gy of irradiation), indicating a higher sensitivity of the smokers to gamma radiation at these doses. At doses of 20-50 Gy, gamma irradiation failed to cause increased DNA damage in smokers, indicating the radio-protective or shielding effect of the tobacco (nicotine) that is possibly related to the antiapoptotic property of nicotine in the targeted/non-targeted cells. This may have important implications for RT that could indicate less effective treatment in smokers. Prolonged exposure to gamma radiation (40-60 Gy) led to a gradual decline in the intensity of the DNA damage, suggesting saturation of DNA damage in the peripheral blood leukocytes\[74\].

One of the cytogenetic biomarkers that is widely used to predict cancer risk in humans is the presence of micronuclei (MN)\[75-77\]. MN are chromosome fragments or whole chromosomes that are not incorporated into the main nucleus during mitosis. Therefore, they only appear in cells that have undergone a nuclear division\[78\]. The MN test is being applied to cytokinesis-blocked peripheral blood lymphocytes and exfoliated cells to monitor human exposure to mutagens\[79-84\]. The evaluation of cytogenetic damage by measuring the frequency of micronucleated cells (MNC) in peripheral blood and buccal mucosa of HNC patients undergoing RT showed a significant increase in the number of MNC during RT. The number of micronucleated lymphocytes remained high 30 to 140 d after the end of treatment. These data confirmed the clastogenic potential of RT in the circulating lymphocytes and buccal cells of HNC patients\[79\] (Figures 1 and 2).

The severity of radiotoxicity can be directly associated with the radiation dosimetry and the dose-volume differences\[76\]. While epidemiological studies have demonstrated the correlation between the formation of a secondary tumor with exposure to moderate-to-high doses of ionizing radiation, a statistically significant increase has hardly been described with low doses of radiation\[77\]. The principal RT effects in normal tissue are acute radiotoxicity (mucositis, dysphagia and dermatitis) that occurs in tissues with rapid turnover rates and late radiotoxicity [subcutaneous skin fibrosis and osteoradionecrosis (ORN)] in tissues with slower turnover rates; these effects may become evident months or years after therapy\[78\]. There are variable normal tissue responses to RT\[85\], and this may be due to the stochastic or deterministic variation effects in radiosensitiveness\[86\]. Mucositis, for in-
stance, is characterized by mucosal ulceration in the oroesophageal and gastrointestinal tract, resulting in pain, dysphagia and diarrhea, depending on the dysfunction of the affected tissue\(^{[80]}.\) Some authors have demonstrated that intestinal mucositis is the consequence of a complex cascade of biological events, rather than solely due to direct clonogenic cell death of the epithelial cells\(^{[80]}.\) However, evidence suggests that EGF and its receptor do not have a critical role in prevention or repair of fluorouracil CT-induced intestinal damage\(^{[83]}.\) In addition to cell death events that are associated with the pathogenesis of mucositis, the activation of a wide variety of transcription factors, the production of proinflammatory cytokines, matrix metalloproteinases, leukotrienes, and ceramide\(^{[81]}.\) caspase activation and the generation of oxidative stress and ROS by chemotherapeutic agents or radiation appear to be primary events in most pathways leading to mucositis. ROS causes DNA damage and subsequent clonogenic cell death in the epithelial layer\(^{[81]}.\) Of the transcriptional factors that may be significant, nuclear factor \(\kappa B\) (NF-\(\kappa B\)), which is activated by either RT or CT, has many of the characteristics that suggest it may be a key element in the genesis of mucositis. Once activated, NF-\(\kappa B\) leads to the up-regulation of many genes, including those that result in the production of the pro-inflammatory cytokines TNF-\(\alpha\), IL-1\(\beta\) and IL-6. This leads to tissue injury and apoptosis\(^{[81]}.\)

Moreover, evidence of genetic mutations and the role of single nucleotide polymorphisms (SNPs) have been shown to underlie the inter-individual differences in the adverse responses of normal tissues to radiation\(^{[83-85]}.\) Interindividual variations in radiotoxicity responses exist despite the uniform treatment protocols. It is speculated that normal genetic variations, particularly SNPs, may influence normal head and neck tissue radiotoxicity\(^{[76]}.\) The first systematic review of the association of SNPs with the occurrence of HNC radiotoxicity evaluated the association of 11 polymorphisms in 8 genes with acute radiotoxicity and 6 polymorphisms in 4 genes for late radiotoxicity\(^{[78]}.\) The risk of severe acute mucositis was associated with the G allele of \(XRCC6\) (1310 C > G), and severe acute dermatitis was associated with the T allele of \(RAD51\) (3392 G > T). The G allele of \(XRCC1\) (1196 A > G) was associated with a lower grade of subcutaneous fibrosis, suggesting that the wild-type alleles were the risk alleles\(^{[86]}.\) ORN was found to be associated with the T allele of the TGF\(\beta 1\) (509 C > T) polymorphism, while the CC genotype was significantly associated with post-extraction related ORN\(^{[78]}\) (Figure 3).

In addition to gene expression changes and DNA damage, microRNAs have been associated with the RT response. In oral SCC cells, it was observed that ICAM2 gene inhibition by miR-125b expression downregulation induces radiosensitization, suggesting that this miRNA was associated with proliferation and radioresistance mechanisms. Therefore, the control of the expression or activity of miR-125b might contribute to the suppression of proliferation and overcoming radioresistance in OSCC\(^{[81]}\).

CT
Cisplatin-based CT is still the standard protocol for treating SCC\(^{[20,88]}\). However, simultaneous treatment with cisplatin, bleomycin (radiomimetic antitumoral drug) and 5-fluorouracil (anti-metabolite drug) has also been used\(^{[89]}\). Other protocols have added paclitaxel to the traditional cisplatin regimen\(^{[90,91]}\). Combinations with methotrexate and docetaxel may be also used. The administration of the combination therapies can be curative or palliative\(^{[92]}\).

Considering that these drugs can induce DNA damage, one of the important late-occurring complications from treatment of the primary tumor is therapy-related secondary cancer that can result from the genotoxic activity of the drugs on healthy cells\(^{[89,93]}\). Desai \textit{et al}\(^{[94]}\) showed that head and neck SCC patients were predisposed to chromosomal rearrangements by anticancer drug treatment, which may promote secondary tumorigenesis. Furthermore, Minicucci \textit{et al}\(^{[95]}\) observed higher frequencies of micronucleated lymphocytes in children with malignant tumors before therapy than in healthy children. The authors suggest that the presence of malig-
Figure 3 Diagram summarizing the genetic variants associated with radiotoxicity. Extracted from Ghazali et al.⁹⁹.

nant tumors may increase the frequency of DNA damage in circulating lymphocytes. Other authors have shown that adjacent tumor tissues shared common genetic changes, and it appears that multiple tumors can arise from a single transforming event that spreads throughout the mucosa surface. On the other hand, some authors have demonstrated the presence of a second tumor that is not clonally-related to the first, which supports the hypothesis of widespread genetic changes after exposure to carcinogen.⁹⁹. In this sense, Ronchetti et al.⁹⁹ studied patients with HNC and found that the pattern of microsatellite changes observed in the primary cancer exhibited a completely different genetic arrangement than the second tumor, indicating an independent origin in about three-quarters of the cases.

Cisplatin activity is based on the formation of DNA adducts that block DNA replication and transcription. These crosslinks represent about 90% of the total DNA damage induced by this drug and are the major contributing factor to its cytotoxic effects.⁹⁹. Carboplatin is another CT drug used for HNC. It belongs to the same class as cisplatin; thus, it is a platinum-based antineoplastic agent. However, when compared to cisplatin, a higher concentration of carboplatin is required to reach equivalent DNA binding because it forms intrastrand DNA crosslinks at a slower rate, and the elimination of free platinum is 10-fold lower than cisplatin.⁹⁹. In relation to treatment with cisplatin, bleomycin and 5-fluorouracil, some authors using the wing somatic mutation and recombination test (Smart) in Drosophila melanogaster (D. melanogaster) have shown that the combination of these drugs produced synergistic and antagonistic genotoxic effects depending on the concentrations used, and these studies suggest that secondary effects associated with their genotoxic effects could exist, emphasizing the importance of long-term monitoring in these patients.¹⁰⁰. The anti-metabolite 5-fluorouracil was developed by Heidelberget et al.¹⁰² and is based on the observation that, during DNA synthesis, the uracil base was used more effectively by tumor cells than normal cells. 5-fluoracil is considered to be an S-phase active chemotherapeutic agent and causes DNA damage, such as double and single-strand breaks.¹⁰³. The genotoxicity of treatment with paclitaxel and cisplatin was also studied, as their effects are not restricted to malignant cells. Using the wing Smart method in D. melanogaster, the authors suggested that the combination of paclitaxel and cisplatin did not appear to increase the risk of secondary cancer development; however, the aneugenic activity of paclitaxel could be responsible for the reduced genotoxicity of cisplatin.¹⁰⁴. Methotrexate blocks the formation of tetrahydrofolate acid because of its high affinity for dihydrofolate reductase and suppresses protein synthesis in the G1 phase. Thus, high dose methotrexate could be possible in combination with leucovorin rescue, which prevents normal cells from being affected by the methotrexate-induced folic acid deficiency.¹⁰⁵.

Effects of the genotype are also observed. In patients with prior HNC, 13-cis-retinoic acid (13-cRA) has been shown to prevent secondary primary tumors (SPT).¹⁰⁶ However, other authors demonstrated that low dose 13-cRA treatment did not significantly reduce the occurrence of SPT. The results seem to be influenced by the genotype of the patient. The GST-M1 genotype is an influential risk factor for the development of SPT. The GST-T1 enzyme demonstrated a protective effect against SPT.¹⁰⁶ To avoid late effects of systemic CT, targeted therapy has been also used for treating HNC patients. Bevacizumab, an antiangiogenic monoclonal antibody that targets vascular endothelial growth factor;⁹⁷; transtuzumab, a monoclonal antibody that targets human epidermal growth factor receptor 2 (HER-2);²⁰⁸; lapatinib, a dual EGFR and HER-2 receptor tyrosine kinase inhibitor;⁹⁷; rapamycin, an mTOR inhibitor with antiproliferative effects;²⁰⁸; sorafenib, an ERCC1 protein expression DNA repair inhibitor²⁰⁸ are some of the drugs currently used.
in target therapy. Among the chemoradiation-induced toxicities, mucosal barrier injury has been well studied. In this sense, peripheral blood cells of patients treated with carboplatinum, paclitaxel and radiation demonstrated the potential impact of the chemoradiation on healthy tissues. Of potential relevance to the development of mucosal injury, it has been observed that Dkk-1, a specific Wnt inhibitor, is upregulated in the tumors. Some authors suggest that the presence of the Wnt inhibitor provides a mechanism for a reduction in epithelial proliferation, as studies have demonstrated that the presence of Dkk-1 is associated with crypt loss in mice.

CONCLUSION
Nowadays, due to advances in cancer therapies, a significant increase of survival has been observed for cancer patients. Reduction of the toxicogenetic or toxicogenomic side effects has been one of the major goals in the search for new anticancer drugs and therapy protocols. Rapid innovations in RT have resulted in an urgent need for methods to predict cancer risks from RT, as direct observation of the late effects of newer treatments will require patient follow-up for a decade or more. Cancer RT involves the eradication of the cancer cells while sparing the surrounding normal tissues. Currently, global tissue responses to RT appear to be directed towards limiting the damage, inducing repair processes and restoring tissue homeostasis. These newer treatments aim to reduce the amount of healthy tissue exposed to high doses of radiation, but this may occur by increasing the amount of normal tissue exposed to lower doses of radiation. Combined chemotherapeutic protocols have also been used aiming synergistic effects and decreased toxicity. Furthermore, the concurrent use of chemo and RT has shown a substantially improvement of survival over the past decades. Alternative therapies, as well as target therapy, have also been developed for treating HNC patients. Prevention of second primary tumors is also a field of research that has increased considerably, because of its impact on long-term survival.

REFERENCES
1. Mitra D, Malkoski SP, Wang XJ. Cancer stem cells in head and neck cancer. *Cancers* (Basel) 2011; 3: 415-427 [PMID: 24212622 DOI: 10.3390/cancers3010415]
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. *Lancet* 2008; 371: 1695-1709 [PMID: 18486742 DOI: 10.1016/S0140-6736(08)6728-X]
3. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. *Methods Mol Biol* 2009; 471: 3-29 [PMID: 19109772 DOI: 10.1007/978-1-59745-416-2_1]
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
5. Prince ME, Alilles LE. Cancer stem cells in head and neck squamous cell cancer. *J Clin Oncol* 2008; 26: 2871-2875 [PMID: 18539966 DOI: 10.1200/JCO.2007.15.1613]
6. Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. *Pathol Res Int* 2011; 2011: 431246 [PMID: 21660266 DOI: 10.4061/2011/2011]
7. Pule D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. *Oncologist* 2010; 15: 994-1001 [PMID: 20798198 DOI: 10.1634/theoncologist]
8. Lippman SM, Sudha J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. *J Clin Oncol* 2005; 23: 346-356 [PMID: 15637397]
9. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. *Cell* 2009; 138: 822-829 [PMID: 19737509 DOI: 10.1016/j.cell.2009.08.017]
10. Okazaki Y, Tanaka Y, Tonogi M, Yamane G. Investigation of environmental factors for diagnosing malignant potential in oral epithelial dysplasia. *Oral Oncol* 2002; 38: 562-573 [PMID: 12167434]
11. Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. *J Oncol* 2012; 2012: 571862 [PMID: 22315596 DOI: 10.1155/2012/571862]
12. Serefoglu Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. *Oral Oncol* 2008; 44: 1093-1099 [PMID: 18486534 DOI: 10.1016/j.oraloncology.2008.02.012]
13. Brown LM, Gridley C, Diefd SB, Winn DM, Harty LC, Otero EB, Fraumeni JF, Hayes RB. Family cancer history and susceptibility to oral carcinoma in Puerto Rico. *Cancer* 2001; 92: 2102-2108 [PMID: 11590626]
14. Tsantroulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. *Oral Oncol* 2007; 43: 523-534 [PMID: 17288495]
15. Taghavi N, Yazdi I. Type of food and risk of oral cancer. *Arch Iran Med* 2007; 10: 227-232 [PMID: 17367228]
16. Elliot MN, Michaud DS, Langevin SM, McClean MD, Kelsey KT. Periodontal disease and mouthwash use are risk factors for head and neck squamous cell carcinoma. *Cancer Causes Control* 2013; 24: 1315-1322 [PMID: 23568534 DOI: 10.1007/s10552-013-0209-x]
17. Stranksy N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Sheller E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auel T, Berger MF, Saksena G, Guacci D, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zaigla J, Winckler W, Ardelie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011; 333: 1157-1160 [PMID: 21798893 DOI: 10.1126/science.1208130]
18. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhrly C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vories EK, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011; 333: 1154-1157 [PMID: 21798987 DOI: 10.1126/science.1209623]
19. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphy A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JM. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. *Oral Oncol* 2006; 42: 430-439 [PMID: 16442835]
20. Braakhus B, Rietbergen M, Buijze M, Snijders P, Bloemena E, Valerius T, Moll HA, van Pelt WJ, Ossendorp F, ten Berge J, Vles JW, van Krieken JHM, van den Bergh B, van Den Heuvel-Beckers MJ, Strumia M, Spagnoli A, di Mambro A, de Vries E, van der Kwast TH, van der Burg SH, van den Berg-Hoogerbrugge E, Vliegenthart RF, van der Zee AG, Beijnen JH, Spauwen PH, Burger P, Heemskerk AM, Klussmann JP, van den Brink CE, Vlak H, Grzegorczyk T, van der Velden-van Zanten SM, van der Bruggen P, Voorhorst EK, van der Schans CP, Buurman WA, Kenter GK, Stoter G, Koppie J, van der Valk P, Kenter MG, Bussink J, van den Bent MJ, HNCOG Study Group. A randomized phase III study of docetaxel and cisplatin with or without cetuximab as neoadjuvant treatment for patients with head and neck squamous cell carcinoma of the pharynx, larynx and hypopharynx: a multicenter HNCOG study. *J Clin Oncol* 2007; 25: 5960-5967 [PMID: 18013192 DOI: 10.1200/JCO.2007.15.1613]
21 Wang NJ, Sanzborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Penny-packer S, Zou Y, Sharma M, North JP, Vemula SS, Mauro TM, Neuhaus IM, Leboit PE, Hur JS, Park K, Huh N, Kwok PY, Arron ST, Massion PP, BAE, Hausler D, Cleaver JE, Gray JW, Spellman PT, South AP, Aster JC, Blacklow SC, Cho RJ. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 2011; 108: 17761-17766 [PMID: 22063358 DOI: 10.1073/pnas.1116696108]

22 Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665 [PMID: 16763280]

23 Agada FO, Alhamarneh O, Stafford ND, Greenman J. Immunotherapy in head and neck cancer: current practice and future possibilities. J Laryngol Otol 2009; 123: 19-28 [PMID: 18761763 DOI: 10.1017/S0022215108003356]

24 Ayllón Barbellido S, Campo Trapero J, Cánovas J, Perea García MA, Escudero Cañasto N, Baconess Martínez A. Gene therapy in the management of oral cancer: review of the literature. Med Oral Patol Oral Cir Bucal 2008; 13: E15-E21 [PMID: 18167474]

25 Corti L, Toniolo L, Bosco C, Gehui F, Flora D, Muzzio PC, Koukourakis MI, Mazzarotto R, Pignataro M, Loreggia L, Sotti G. Long-term survival of patients treated with photo-dynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg Med 2007; 39: 394-402 [PMID: 17565719]

26 Pendleton KP, Grandis JR. Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Prev 2013; 6: 1-11 [PMID: 24273416 DOI: 10.4137/CMT.S10409]

27 Epstein JB, Thariat J, Bensadoun RJ, Jarash A, Murphy BA, Kolnick L, Popplewell L, Maghami E. Oralc complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012; 62: 400-422 [PMID: 22972542 DOI: 10.3322/caac.21157]

28 Lung T, Täsćzu OC, Almăşan HA, Mureşan O. Head and neck cancer, treatment, evolution and post therapeutic survival - Part 2: a decade’s results 1993-2002. J CranioMaxilloFac Surg 2003: 31: 174-181 [PMID: 12445452]

29 Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85: 156-170 [PMID: 17482300]

30 Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol 2008; 35: 236-250 [PMID: 18544439 DOI: 10.1053/j.seminoncol.2008.03.0032]

31 Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146 [PMID: 3390344]

32 Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25: 4066-4074 [PMID: 17824545]

33 Lee SY, Park HR, Cho NH, Choi YP, Rha SY, Park SW, Kim SH. Identifying genes related to radiation resistance in oral squamous cell carcinoma cell lines. Int J Oral Maxillofac Surg 2007; 36: 136-141 [PMID: 17494619]

34 Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol 2011; 100: 22-32 [PMID: 21513135 DOI: 10.1016/j.radonc.2011.03.004]

35 Hosokawa Y, Okumura K, Terashima S, Sakakura Y. Radiation protective effect of hypoxia-inducible factor-1α (HIF-1α) on human oral squamous cell carcinoma cell lines. Radiat Prot Dosimetry 2012; 152: 159-163 [PMID: 22927657 DOI: 10.1093/rpd/ncs215]

36 Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 435-439 [PMID: 11010718]

37 Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3: 117-129 [PMID: 12563311]

38 Yang S, Chen J, Guo Y, Lin H, Zhang Z, Feng G, Hao Y, Cheng J, Liang P, Chen K, Wu H, Li Y. Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients. Int J Oncol 2012; 40: 1590-1600 [PMID: 22267578 DOI: 10.3892/ijo.2012.2341]

39 Bohn SK, Rissnes KM, Sakki AK, Thoresen M, Holden M, Moskau JO, Myhrstad MC, Olstad OK, Smeland S, Blomhoff R. Stress associated gene expression in blood cells is related to outcome in radiotherapy treated head and neck cancer patients. BMC Cancer 2012; 12: 426 [PMID: 23099663 DOI: 10.1186/1471-2407-12-426]

40 Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425 [PMID: 11861608]

41 Facciponte JG, Wang XY, MacDonald JJ, Park JE, Arnouk H, Grimm M, Li Y, Kim H, Manjielli MH, Easton DP, Subjeck JR. Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother 2006; 55: 339-346 [PMID: 16032990]

42 Demine R, Walden P. Testing the role of gp96 as peptide chaperone in antigen processing. J Biol Chem 2005; 280: 17573-17578 [PMID: 15728573]

43 Randow F, Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol 2001; 3: 891-896 [PMID: 11584270]

44 Schild H, Ramseeree HG. gp96—the immune system’s Swiss army knife. Nat Immunol 2000; 1: 100-101 [PMID: 11286796]

45 Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol Cells 2005; 20: 173-182 [PMID: 16267590]

46 Lin CY, Lin TY, Wang HM, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Li YL, Chen YJ, Cheng AJ, Chang JT. GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. Radiat Oncol 2011; 6: 136 [PMID: 21992474 DOI: 10.1186/1748-717X-6-136]

47 Parshad R, Sanford KK. Radiation-induced chromatin breaks and deficient DNA repair in cancer predisposition. Crit Rev Oncol Hematol 2007; 63: 87-96 [PMID: 17165852]

48 Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment-tumorigenesis and therapy. Nat Cancer 2005; 5: 867-875 [PMID: 16327765]

49 Engels H, Wambersie A. Relative biological effectiveness of neutrons for cancer induction and other late effects: a review of radiobiological data. Recent Results Cancer Res 1998; 150: 54-87 [PMID: 9670283]

50 Kaiser HE, Nasir A, Groger AM, Link CJ. The etiology of the second primary neoplasms. In Vico 1998; 12: 89-93 [PMID: 9575431]

51 Perel Y, Leverger G, Carrere A, Caudry M, Garabedian EN, Ansborlo S, Vergnes P. Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia. Ann J Hematol 1998; 59: 91-94 [PMID: 9725885]

52 Roszkowski K, Gackowski D, Rozalski R, Dziama T, Siomek A, Guz J, Szpila A, Foksinski M, Olimski R. Small field radiotherapy of head and neck cancer patients is responsible for oxidatively damaged DNA/oxidative stress on the level of a whole organism. Int J Cancer 2008; 123: 1964-1967 [PMID: 18688851 DOI: 10.1002/ijc.23700]

53 Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol 2003; 13: 248-266 [PMID: 12930041]

54 Allan JM, Travis LB. Mechanisms of therapy-related carci-
nogenesis. *Nat Rev Cancer* 2005; 5: 943-955 [PMID: 16294218]

55 Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. *Crit Rev Oral Biol Med* 2004; 14: 199-212 [PMID: 12793932]

56 Roch-Lefèvre R, Pouzoulet F, Giraudet AL, Voisin P, Vaurijoux A, Gruel G, Grégoire E, Buard V, Delbos M, Voisin P, Bourhis J, Roy L. Cytogenetic assessment of heterogeneous radiation doses in cancer patients treated with fractionated radiotherapy. *Br J Radiol* 2010; 83: 759-766 [PMID: 20739344 DOI: 10.1259/bjr/21022597]

57 Rusin P, Oleszewski J, Morawiec-Bajda A, Przybyłowska K, Kaczmarczyk D, Golinska A, Majsterek I. Comparative study of DNA damage and repair in head and neck cancer after radiation treatment. *Cell Biol Int* 2009; 33: 357-363 [PMID: 19385033]

58 Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. *Acta Oncol* 2008; 47: 809-824 [PMID: 18566480 DOI: 10.1080/02841860801895896]

59 Thacker J, Zdziennicka MZ. The XRCC genes: expanding roles in DNA double-strand break repair. *DNA Repair* (Amst) 2004; 3: 1081-1090 [PMID: 15279796]

60 Werbrouck J, De Ruycq K, Duprez F, Veldenman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thiérens H. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. *Int J Radiat Oncol Biol Phys* 2009; 73: 1187-1195 [PMID: 19251090 DOI: 10.1016/j.ijrobp.2008.07.073]

61 Pratesi N, Mangoni M, Mancini I, Paiar F, Simi L, Livi L, Cassi D, Buglione M, Grisanti S, Almici C, Polli C, Saicva C, Magrini SM, Bitti G, Pazzagli M, Orlando C. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. *Radiother Oncol* 2011; 99: 356-361 [PMID: 21704413 DOI: 10.1016/j.radonc.2011.05.062]

62 Faust F, Kassie F, Krasnusamöller S, Boederke RH, Mann M, Mersch-Sundermann V. The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. *Mutat Res* 2004; 566: 209-229 [PMID: 15882238]

63 Kanvah S, Andreassen CN, Minicucci EM, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagman L, Joksic G, Martelli A, Migliore I, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. *Carcinogenesis* 2007; 28: 625-631 [PMID: 16973674]

64 Murgia E, Ballardin M, Bonassi S, Rossi AM, Barale R. Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study. *Mutat Res* 2008; 639: 27-34 [PMID: 18150701]

65 Fenech M, Morley A. Solutions to the kinetic problem in the micronucleus assay. *Cytobios* 1985; 43: 233-246 [PMID: 4075848]

66 Majer BJ, Laky B, Krasnusamöller S, Kassie F. Use of the micronucleus assay with exfoliated epithelial cells as a biomarker for monitoring individuals at elevated risk of genetic damage and in chemoprevention trials. *Mutat Res* 2001; 489: 147-172 [PMID: 11741033]

67 Albertini RJ, Anderson D, Douglas GR, Hagman L, Hemminki K, Merlo F, Natarajan AT, Norppa H, Shucker DE, Tice R, Waters MD, Aitio A. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. *Mutat Res* 2000; 463: 111-172 [PMID: 10913908]

68 León-Mejía G, Espitia-Pérez L, Hoyos-Giraldo LS, Da Silva J, Hartmann A, Henrique JA, Quintana M. Assessment of DNA damage in coal open-cast mining workers using the cytokinesis-blocked micronucleus test and the comet assay. *Sci Total Environ* 2011; 409: 686-691 [PMID: 21215992 DOI: 10.1016/j.scitotenv.2010.10.049]

69 Minicucci EM, Kowalski LP, Maia MA, Pereira A, Ribeiro LR, de Camargo JL, Salvadori DM. Cytogenetic damage in circulating lymphocytes and buccal mucosa cells of head-and-neck cancer patients undergoing radiotherapy. *Int J Radiat Oncol Biol Phys* 2010; 76: S145-S150 [PMID: 20175150 DOI: 10.1016/j.ijrobp.2009.08.076]

70 Suzuki K, Yamashita S. Low-dose radiation exposure and carcinogenesis. *Ipn J Clin Oncol* 2012; 42: 563-568 [PMID: 22641644 DOI: 10.1016/j.jjco.2012.04.010]

71 Ghazali N, Shaw RJ, Rogers SN, Rask JM. Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. *Oral Oncol* 2012; 48: 1090-1100 [PMID: 22939215 DOI: 10.1016/j.oraloncology.2012.08.002]

72 Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. *Int J Radiat Oncol Biol Phys* 2010; 76: S150-S151 [PMID: 19015485 DOI: 10.1016/j.ijrobp.2009.08.076]

73 Fenech M, Kemp CJ, Williams JL, Erwin CR, Warner BW. Role of epidermal growth factor and its receptor in chemotheraphy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. *Cancer* 2004; 100: 1995-2025 [PMID: 15108222]

74 Huang FS, Kemp CJ, Williams JL, Erwin CR, Warner BW. Role of epidermal growth factor and its receptor in chemo-therapy-induced intestinal injury. *Am J Physiol Gastrointest Liver Physiol* 2002; 282: G432-G442 [PMID: 11841993]

75 Andreassen CN, Alsen J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. *Radiother Oncol* 2009; 92: 299-309 [PMID: 19683821 DOI: 10.1016/j.radonc.2009.06.015]
Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharaoa PD, Burnet NG. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotyping. Nat Rev Cancer 2009; 9: 134-142 [PMID: 19148183 DOI: 10.1038/nrc25897].

Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radiosensitivity. Semin Radiat Oncol 2010; 20: 232-240 [PMID: 20832015 DOI: 10.1016/j.sramdon.2010.05.003].

Alsbeih G, Al-Harbi N, Al-Hadyan K, El-Sebaie M, Al-Raihi N. Association between normal tissue complications after radiotherapy and polymorphic variations in TGFβ1 and XRCC1 genes. Radiat Res 2010; 173: 505-511 [PMID: 20334523 DOI: 10.1667/RR1769].

Shibb M, Shinozuka K, Saito K, Fushimi K, Kasamatsu R, Ribeiro DA, de Camargo B, Costa MC, Ribeiro LR, Favero Salvadori DM. DNA damage in lymphocytes and buccal mucosa cells of children with malignant tumours undergoing chemotherapy. Clin Exp Med 2009; 9: 79-85 [PMID: 18618217 DOI: 10.1007/s10028-008-0161-3].

Ha PK, Calilano JA. The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 2003; 14: 363-369 [PMID: 14553034].

Ronchetti D, Arisi E, Neri A, Pruner G, Digiuni B, Sambataro G, Gallo O, Pignataro L. Microsatellite analyses of recurrence or second primary tumor in head and neck cancer. Anticancer Res 2005; 25: 2771-2775 [PMID: 16080525].

Garcia Sar D, Montes-Bayón M, Aguado Ortiz L, Blanco-González E, Sierra LM, Sanz-Medel A. In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal Bioanal Chem 2007; 390: 37-44 [PMID: 17932658].

Bhana S, Heezer A, Phillips DH, Lloyd DR, p53-dependent global nucleotide excision repair of cisplatin-induced intratrad cross links in human cells. Mutagenesis 2008; 23: 131-136 [PMID: 18267499].

Knof RJ, Friedlos F, Lyddall DA, Roberts J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diaminedichloroplatinum(II) and cis-diamine-(1,1-cyclobutane dicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-1979 [PMID: 3512077].

Danesi CC, Dihi RR, Bellagamba BC, de Andrade HH, Cunha KS, Guimarães NN, Lehmann M. Genotoxicity testing of combined treatment with cisplatin, bleomycin, and 5-fluorouracil in somatic cells of Drosophila melanogaster. Mutat Res 2012; 747: 228-233 [PMID: 22640881 DOI: 10.1016/j.mrgentox.2012.05.009].

Heidelbergber C, Chaudhuri NK, Danneberg P, Mooreen D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666 [PMID: 13418758].

Peters GJ, van Triest B, Backus HH, Kuiper CM. Comparison of paclitaxel and cisplatin in head and neck cancer: implications for field cancerization. Eur J Cancer 2000; 36: 916-924 [PMID: 10785598].

Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G, Awada A. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006; 28: 256-269 [PMID: 16284973].

Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, Halfy BG. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorscence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002; 8: 540-548 [PMID: 11839675].

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94 [PMID: 12467226].

Aissat N, Le Tourneau C, Ghoul A, Serova M, Biache L, Lokic F, Raymond E, Fairev S. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-313 [PMID: 17912526].

Yadav A, Kumar B, Teknos TN, Kumar P. Soralenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCCE-1 DNA repair proteins. Mol Cancer Ther 2011; 10: 1241-1251 [PMID: 21551262 DOI: 10.1186/1555-7163-MCT-11-0004].

Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mooakamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007; 43: 289-300 [PMID: 16920886].
113 **Kuhnert F**, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. *Proc Natl Acad Sci USA* 2004; **101**: 266-271 [PMID: 14699865]

114 **Hall EJ**, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys* 2003; **56**: 83-88 [PMID: 12694826]

115 **Berrington de Gonzalez A**, Gilbert E, Curtis R, Inskip P, Kleinerman R, Morton L, Rajaraman P, Little MP. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys* 2013; **86**: 224-233 [PMID: 23102695 DOI: 10.1016/j.ijrobp.2012.09.001]

**P- Reviewers:** Kawamata H, Sanabria A  **S- Editor:** Zhai HH  
**L- Editor:** A  **E- Editor:** Liu SQ
